Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure

Recruiting now · Not applicable

Conditions studied: ESRD (End-Stage Renal Disease), Maintenance Hemodialysis

In brief

Patients on maintenance hemodialysis (MHD) face a high risk of cardiovascular mortality and reduced quality of life. Conventional high-flux hemodialysis (HD) is the standard of care but has limited efficacy in clearing middle-molecular and protein-bound uremic toxins (PBUTs). The accumulation of these toxins is associated with adverse long-term outcomes. This study evaluates the efficacy and safety of the pHA130 hemoadsorption cartridge, which utilizes a modified resin for enhanced PBUT adsorption, when combined with hemodialysis (HAHD). This is a prospective, open-label, multi-center, randomized controlled trial involving 100 MHD patients. Participants will be randomized 1:1 to either the HAHD group (receiving one HAHD session using the pHA130 cartridge and two standard HD sessions weekly) or the Control group (receiving three standard HD sessions weekly). The primary objective is to assess the reduction in serum indoxyl sulfate (IS) and p-cresol sulfate (PCS) levels from baseline to 12 months. Secondary objectives include evaluating changes in quality of life (KDQoL-SF, MMSE), the progression of coronary artery calcification (CAC), the incidence of major adverse cardiovascular events (MACEs), all-cause mortality, and safety profiles. This trial aims to determine if integrating long-term HAHD therapy can optimize blood purification strategies for the MHD population.

Key facts

Study ID: NCT07656168
Run by: China-Japan Friendship Hospital
People needed: 100
Starts: 2026-06-01
Expected to finish: 2028-08-01
Last updated by the study team: 2026-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age > 18 years.
On maintenance hemodialysis for > 3 months.
Receiving hemodialysis 3 times per week, 4 hours per session.
Standard Kt/V ≥ 1.2.
Voluntarily participates and provides written informed consent.

You may not qualify if…

Known allergy to the dialyzer or hemoperfusion device.
Platelet count < 60×10⁹/L.
Serum albumin < 30 g/L.
24-hour urine output > 200 ml.
Inability to achieve a blood flow rate ≥ 200 ml/min.
Coagulation disorders, severe bleeding tendency, or active bleeding.
Pre-dialysis systolic blood pressure < 90 mmHg or diastolic blood pressure < 60 mmHg.
Active malignancy.
Active infection, or severe, critical illness of cardiac, pulmonary, hepatic, or nervous systems.
Planned living-donor kidney transplant within the next 6 months.
Current participation in another interventional clinical study, or participation within the past 3 months in an interventional study that may interfere with the present study (e.g., fecal microbiota transplantation); or use of intestinal microecological regulators such as probiotics.
History of unstable angina, myocardial infarction, malignant arrhythmia, cardiac or peripheral vascular surgery, or cerebrovascular accident within the past 8 weeks.

Where it is running

China-Japan Friendship Hospital — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.